Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 3,775 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Type 2 Diabetes Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy

NCT01837680
View directory record Official record
Conditions
Diabetes, Gestational, Diabetes, Type 2
Interventions
Insulin
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 25, 2026, 2:59 AM EDT
Terminated No phase listed Observational

Progression of Diabetic Retinopathy Post Bariatric Surgery (BS)

NCT01393873
View directory record Official record
Conditions
Obesity, Diabetes Mellitus
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Oct 25, 2026, 2:59 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease

NCT01101269
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ACEI or ARB, Lisinopril
Drug
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 25, 2026, 2:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Adiponectin and Ethnic Differences in Insulin Resistance

NCT01831102
View directory record Official record
Conditions
Insulin Resistance, Type 2 Diabetes
Interventions
none- observational study
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 15, 2013 · Synced Oct 25, 2026, 2:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oxygenation Changes After 2-month Exercise in Sedentary Older Adults With Diabetes

NCT04626453
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Oxygen Deficiency
Interventions
2-month home moderate-intensity exercise
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
60 Years and older
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Oct 25, 2026, 2:59 AM EDT
Completed Not applicable Interventional

Impact of Accu-Chek 360 in Veterans With Type 2 Diabetes

NCT00824694
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Targeted Self-Monitoring Of Blood Glucose (SMBG), Provider Training, Patient Education
Other
Lead sponsor
Biomedical Research Institute of New Mexico
Other
Eligibility
18 Years to 85 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Phoenix, Arizona • Tucson, Arizona • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Oct 25, 2026, 2:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State

NCT01002807
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Dapagliflozin, Metformin XR, Glucophage
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 25, 2026, 2:59 AM EDT
Completed Not applicable Interventional Results available

Pilot Study to Assess the Effects of Hepatic Ultrasound Insonification on Subjects With T2DM

NCT04502212
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Hepatic Ultrasound Insonification
Device
Lead sponsor
General Electric Research
Industry
Eligibility
21 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 25, 2026, 2:59 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186

NCT05694741
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
AZD0186, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 25, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

NCT00528372
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Dapagliflozin placebo, Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
1,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
38
States / cities
Phoenix, Arizona • Tempe, Arizona • Fresno, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Oct 25, 2026, 2:59 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes

NCT02097277
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
BMS-986036, Placebo (Matching with BMS-986036)
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Little Rock, Arkansas • Anaheim, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 25, 2026, 2:59 AM EDT
Completed Not applicable Interventional

Diabetes Mellitus Type 2 Basal Insulin Dosing Requirements Study

NCT00874809
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
CGMS with an insulin pump using rapid acting insulin
Device
Lead sponsor
Diabetes Care Center
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Salinas, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Oct 25, 2026, 2:59 AM EDT
Completed Phase 3 Interventional

A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy

NCT00823992
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
placebo, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
29
States / cities
Bermuda Dunes, California • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Oct 25, 2026, 2:59 AM EDT
Completed Not applicable Interventional Results available

Improving Chronic Disease Management With Pieces

NCT02587936
View directory record Official record
Conditions
Chronic Kidney Disease, Diabetes, Hypertension, High BP, Type 2 Diabetes
Interventions
Collaborative Model of Primary care and Subspecialty care
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
18,268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Farmington, Connecticut • Arlington, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 25, 2026, 2:59 AM EDT
Completed No phase listed Observational

Non-traditional Cardiovascular Risk Factors and Atherosclerosis in Type 2 Diabetes

NCT00256607
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
40 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 25, 2026, 2:59 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Role of Microvascular Insulin Resistance and Cardiorespiratory Fitness Diabetes

NCT04791371
View directory record Official record
Conditions
Type 2 Diabetes, Overweight and Obesity
Interventions
Cardiovascular exercise
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 55 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 25, 2026, 2:59 AM EDT
Not listed Phase 1 Interventional

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

NCT02059564
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
HM11260C, Placebo, Victoza
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
California City, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Oct 25, 2026, 2:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Digital Health Tool for Insulin Titration (DHIT) Individuals With Type 2 Diabetes: A Prospective Outcomes Study With a Retrospective Control Group

NCT03138447
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Basal Insulin Titration Application
Device
Lead sponsor
Amalgam Rx, Inc.
Industry
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 25, 2026, 2:59 AM EDT
Completed Phase 1 Interventional

A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease

NCT03060538
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Non-Alcoholic Fatty Liver Disease
Interventions
BFKB8488A, Placebo
Drug · Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Anniston, Alabama • Coronado, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 25, 2026, 2:59 AM EDT
Completed Phase 1 Interventional

A Feasibility Study to Assess Critical Aspects of Fluorescence Affinity Sensor (FAS) Performance and Safety Over Several Hours

NCT01065948
View directory record Official record
Conditions
Diabetes
Interventions
Subcutaneous glucose monitoring device
Device
Lead sponsor
BioTex, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 25, 2026, 2:59 AM EDT
Completed Not applicable Interventional Results available

Evaluating a Type 2 Diabetes Prevention Program

NCT05822648
View directory record Official record
Conditions
Type 2 Diabetes, PreDiabetes
Interventions
Project Health, Educational Video Control
Behavioral · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 25, 2026, 2:59 AM EDT
No Longer Available No phase listed Expanded access

Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder

NCT01798914
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Technosphere Insulin Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
14
States / cities
Montgomery, Alabama • Miami, Florida • Orland Park, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 25, 2026, 2:59 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Effect of ASP1941 in Combination With Metformin in Adult Patients With Type 2 Diabetes Mellitus

NCT01117584
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
ipragliflozin, Placebo, Metformin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Los Angeles, California • Coral Gables, Florida • Hialeah, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 25, 2026, 2:59 AM EDT
Completed Phase 4 Interventional Results available

Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes

NCT00123604
View directory record Official record
Conditions
Hypertension, Type 2 Diabetes Mellitus
Interventions
Carvedilol, Metoprolol
Drug
Lead sponsor
St. Paul Heart Clinic
Other
Eligibility
30 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 25, 2026, 2:59 AM EDT